Biomarker Testing and Treatment Approach in NSCLC

 

Masonic Cancer Center, University of Minnesota
L

EGFRm NSCLC: Resistance Mechanisms, Role of DARPP-32 in Tumor Growth

By Masonic Cancer Center, University of Minnesota FEATURING Luke Hoeppner
By Masonic Cancer Center, University of Minnesota FEATURING Luke Hoeppner
38 views
May 26, 2021
0 Comments
Login to view comments. Click here to Login
Biomarker Testing and Treatment Approach in NSCLC
11:46
Moffitt Cancer Center

ASCO 2021 Updates from the PACIFIC Trial: Five-Year Survival Outcome…

Feat. A. Chiappori
16:21
City of Hope

Prevalence of EGFR Mutation Testing in Early Stage Lung Cancer: Impl…

Feat. E. Massarelli
19:41
Masonic Cancer Center

EGFRm NSCLC: Resistance Mechanisms, Role of DARPP-32 in Tumor Growth

Feat. L. Hoeppner
15:47
Association of Community Cancer Centers (ACCC)

Advanced NSCLC: Receiving the Reports & Treatment Decisions

Feat. C. Presley
09:12
Jonathan Goldman

Targeted Adjuvant Therapy for Lung Cancer: The ADAURA Trial

60:29
Total Health

Virtual Evolution on NSCLC: Case Panel Discussion on Surgical Consid…

Feat. S. Kazmi, M. Das, E. Gillaspie, K. Keane
12:44
Penn Medicine Abramson Cancer Center

Advances in Adjuvant Therapy in NSCLC

Feat. C. Ciunci
08:22
Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

Molecular Drivers in Lung Cancer: Overview of EGFR Targeted Therapy …

Feat. J. Nieva
11:38
Natasha Leighl

WCLC 2021: Incorporating ctDNA Into the Management of Advanced NSCLC…

42:57
Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

[private by partner request] Updates on Early Stage Lung Cancer: Cha…

Feat. L. Backhus
24:02
Keck School of Medicine of USC Advancing Knowledge in Multidisciplinary Lung Cancer Care

Curative Intent Surgical Management of Advanced Primary Lung Cancer

Feat. S. Atay
15:51
Debora Bruno

ASCO 2021 Update on Racial Disparities in Biomarker Testing and Clin…